SCHEMBL21247366

SCHEMBL21247366

O=C(Nc1sc2c(c1C(=O)O)CCC2)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 1.00
MAPT P10636 5/20 1.00
POLB P06746 2/20 1.00
LMNA P02545 1/20 1.00
HPGD P15428 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
ESR2 Q92731 1/20 1.00
CTDSP1 Q9GZU7 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
MEN1 O00255 12/20 0.92
KMT2A Q03164 12/20 0.92
NPC1 O15118 6/20 0.92
ALDH1A1 P00352 1/20 0.92
CASP3 P42574 1/20 0.81
SENP7 Q9BQF6 1/20 0.81
L3MBTL1 Q9Y468 2/20 0.79
TNF P01375 3/20 0.76
NOD1 Q9Y239 3/20 0.76
FLT3 P36888 1/20 0.76
GRIN2C Q14957 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916274 0.97 KMT2A (0.97) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL919352 0.96 MEN1 (1.00) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL5453337 0.89 RAB9A (1.00) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL3128198 0.86 FLT3 (1.00) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL7894754 0.86 MEN1 (1.00) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL8206445 0.85 TP53 (0.80) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL8289672 0.85 FLT3 (0.97) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL21247135 0.84 MEN1 (1.00) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL918590 0.84 MEN1 (0.79) RAB9AMAPTPOLBLMNAHPGD
SCHEMBL918663 0.84 MEN1 (1.00) RAB9AMAPTPOLBLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603368-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-03-14 US disclosed
EP-3749658-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP disclosed
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154949-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
WO-2019154949-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH RAB9A 1824/4885MAPT 2107/4885POLB 3971/4885
US-11603368-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH RAB9A 1824/4885MAPT 2107/4885POLB 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.